TEVA DENMARK A/S
CVR: 29634076
Secondary names: TEVA NORDIC A/S, Actavis Nordic A/S, 2K Pharma A/S
TEVA DENMARK A/S demonstrates a positive financial trajectory, with revenue increasing from 411.4 million DKK in 2022 to 632.2 million DKK in 2024, alongside a rise in profit from 41.2 million DKK to 57.4 million DKK over the same period. The company's equity has seen a decline from 209.4 million DKK in 2023 to 166.9 million DKK in 2024, which raises some concerns regarding its financial stability. Despite this, the significant growth in both revenue and profit indicates strong operational performance and a recovery from previous losses in 2020. Positioned within the wholesale trade of pharmaceuticals and healthcare products, TEVA Denmark appears to be strengthening its market presence, although careful monitoring of its equity and margins is advisable.
AI-generated summary
Overview
Details
Contact
Advertising protectedPurpose
Selskabets formål er : (a) at importere/eksportere, registrere, markedsføre og distribuere lægemidler og relaterede produkter til brug for mennesker eller dyr, (b) at stifte, have andel i, administrere, rådgive, auditere, samarbejde med, forestå ledelsen af og yde tjenester til andre selskaber og virksomheder, samt finansiere andre selskaber og virksomheder, og (c) at udføre enhver aktivitet, som måtte være relateret til eller befordrende for ovenstående i bredest mulige forstand. Selskabet kan stille sikkerhed, pantsætte aktiver, garantere for opfyldelsen af samt forpligte sig særskilt eller på anden vis for betalingen af koncernselskabers og/eller tredjemands gæld.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 632.2 mio. | 57.4 mio. | 325.7 mio. | 166.9 mio. | 37 | |
History
Ownership
Management
Directors
Board
Founders
Production units (1)
Similar companies
Companies in the same industry and area